Man Group
RARE icon

Man Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Man Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.51M Sell
195,110
-18,242
-9% -$453K 0.01% 1000
2026
Q1 		$4.47M Buy
213,352
+134,981
+172% +$3.04M 0.01% 1213
2025
Q4 		$1.8M Buy
78,371
+71,219
+996% +$2.34M ﹤0.01% 1485
2025
Q3 		$215K Sell
7,152
-177,025
-96% -$5.31M ﹤0.01% 2090
2025
Q2 		$6.7M Sell
184,177
-270,971
-60% -$9.77M 0.01% 932
2025
Q1 		$16.5M Buy
455,148
+157,754
+53% +$6.56M 0.04% 524
2024
Q4 		$12.5M Sell
297,394
-29,809
-9% -$1.48M 0.03% 640
2024
Q3 		$18.2M Sell
327,203
-301,523
-48% -$15.4M 0.05% 482
2024
Q2 		$25.8M Buy
628,726
+475,085
+309% +$20.3M 0.07% 358
2024
Q1 		$7.17M Buy
153,641
+65,830
+75% +$3.11M 0.02% 839
2023
Q4 		$4.2M Buy
+87,811
New +$3.4M 0.01% 1022
2023
Q3 		– Sell
-42,277
Closed -$1.68M – 1381
2023
Q2 		$1.95M Buy
+42,277
New +$1.96M 0.01% 1209
2023
Q1 		– Sell
-38,211
Closed -$1.64M – 1402
2022
Q4 		$1.77M Buy
38,211
+3,773
+11% +$148K 0.01% 1151
2022
Q3 		$1.43M Buy
+34,438
New +$1.77M 0.01% 1176
2022
Q2 		– Sell
-6,724
Closed -$414K – 1224
2022
Q1 		$488K Buy
+6,724
New +$468K ﹤0.01% 1592
2021
Q2 		– Sell
-16,645
Closed -$1.9M – 2069
2021
Q1 		$1.9M Sell
16,645
-28,503
-63% -$3.88M 0.01% 1126
2020
Q4 		$6.25M Buy
45,148
+12,555
+39% +$1.49M 0.03% 675
2020
Q3 		$2.68M Buy
32,593
+4,016
+14% +$333K 0.01% 1090
2020
Q2 		$2.23M Sell
28,577
-8,771
-23% -$581K 0.01% 1024
2020
Q1 		$1.66M Sell
37,348
-58,795
-61% -$3.05M 0.01% 961
2019
Q4 		$4.11M Buy
96,143
+44,797
+87% +$1.85M 0.01% 1065
2019
Q3 		$2.2M Sell
51,346
-16,217
-24% -$881K 0.01% 1212
2019
Q2 		$4.29M Sell
67,563
-10,142
-13% -$646K 0.02% 1015
2019
Q1 		$5.39M Buy
77,705
+34,662
+81% +$1.98M 0.02% 879
2018
Q4 		$1.87M Sell
43,043
-6,341
-13% -$347K 0.01% 1246
2018
Q3 		$3.77M Buy
+49,384
New +$4.02M 0.01% 1147

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Man Group's RARE Position: Q2 2026 in Review

Man Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 8.6% in Q2 2026, selling an estimated $453K and leaving 195,110 shares worth $6.51M. The position accounts for 0.01% of the portfolio, ranked #1000.

Man Group first reported a position in RARE in Q3 2018 and has held it in 26 quarters since. The position peaked at $25.8M in Q2 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Man Group held 195,110 shares of Ultragenyx Pharmaceutical worth $6.51M as of Q2 2026.
  • Man Group sold 18,242 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $453K.
  • Ultragenyx Pharmaceutical made up 0.01% of Man Group's portfolio in Q2 2026, its #1000 holding.
  • Man Group first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and has held it in 26 quarters since.
  • Man Group's Ultragenyx Pharmaceutical position peaked at $25.8M in Q2 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.